Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | Prospect of new therapies for AML

Mhairi Copland • 29 Mar 2017
BSH 2017
Acute Myeloid Leukemia

Mhairi Copland, PhD, MB, ChB, MRCP, FRCPath from the University of Glasgow, Glasgow, UK, gives an overview of the session on targeted therapy and immunotherapy for acute myeloid leukemia (AML) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. Copland discusses clinical trials in the UK and the prospect of new therapies for AML.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Mhairi Copland

Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
3:00
Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
Mhairi Copland • 4 Sep 2025
How the management of CML is evolving & future directions
1:18
How the management of CML is evolving & future directions
Mhairi Copland • 5 Sep 2025
Current and future treatment strategies for blast-phase CML
3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
The importance of improving treatment-free remission in patients with CML
1:36
The importance of improving treatment-free remission in patients with CML
Mhairi Copland • 29 Sep 2022

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals